Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. [electronic resource]
Producer: 20160509Description: 313-20 p. digitalISSN:- 1468-3288
- Adult
- Cohort Studies
- Female
- Hepatitis B Antibodies -- analysis
- Hepatitis B e Antigens -- immunology
- Hepatitis B, Chronic -- immunology
- Humans
- Interferon-alpha -- therapeutic use
- Male
- Nucleosides -- therapeutic use
- Polyethylene Glycols -- therapeutic use
- Recombinant Proteins -- therapeutic use
- Retrospective Studies
- Sensitivity and Specificity
- Seroconversion
No physical items for this record
Publication Type: Clinical Trial, Phase IV; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.